BackGongwin Biopharm Holdings , Ltd. Overview

Gongwin Biopharm Holdings , Ltd. Receivables

Track Gongwin Biopharm Holdings , Ltd.'s receivables ($20M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$19.94M
↓ 18.97% YoYΔ $-4.67M vs prior year quarter

Peer trimmed avg / median

Loading

Gongwin Biopharm Holdings , Ltd. Receivables History

Loading

Gongwin Biopharm Holdings , Ltd. vs. peers: Receivables Comparison

Loading

Gongwin Biopharm Holdings , Ltd. Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Gongwin Biopharm Holdings , Ltd. (6617.TWO) FAQ

Gongwin Biopharm Holdings , Ltd. posts a receivables of $20M as of June 2026. That compares with $25M in the prior-year period — down 19.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Gongwin Biopharm Holdings , Ltd.'s receivables was $25M. The latest reading is $20M — a 19.0% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Gongwin Biopharm Holdings , Ltd.'s financial statement story. At $20M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 6617.TWO's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Gongwin Biopharm Holdings , Ltd.'s other metric pages and overview cover the third.